Skip to main content

Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present


Ovarian cancer is composed of a complex system of cells best described by features such as clonal evolution, spatial and temporal genetic heterogeneity, and development of drug resistance, thus making it the most lethal gynecologic cancer. Seminal work on cancer as an evolutionary process has a long history; however, recent cost-effective large-scale molecular profiling has started to provide novel insights coupled with the development of mathematical algorithms. In the current review, we have systematically searched for articles that focused on the clonal evolution of ovarian cancer to offer the whole landscape of research that has been done and highlight future research avenues given its characteristic features and connections to evolutionary biology.


Worldwide, each year more than 300.000 new cases of ovarian cancer are diagnosed and 185.000 patients succumb to their disease [1], without any major improvement in the long-term overall survival over the past three decades, despite improved disease control rates measured as 5-year overall survival [2].

As Theodosius Dobzhansky said in a seminal paper in 1973 that “Nothing in biology makes sense except in the light of evolution” [3], Darwinian principles applied in cancer science have brought much to our current understanding of this disease, and ovarian cancer makes no exception [4, 5]. The high incidence of ovarian cancer can also be attributed to an evolutionary mismatch to our rapid social evolution. The rising incidence in industrialized societies can be partly explained by reproductive patterns such as increased total number of ovulations, increased age at first birth, fewer pregnancies [6, 7], and a prolonged estrogen exposure [8] with partial attenuation through the introduction of oral contraceptives but predicted increases for the following years [9]. Interestingly, the high prevalence of founder BRCA1/2 mutation carriers can be explained by their increased lifetime reproductive success in natural fertility conditions that also masked their detrimental oncogenic potential for cancers of the reproductive tract [10, 11].

Within its natural history, ovarian cancer is generally a disease that remains localized to the peritoneal cavity throughout its course, with occasional distant metastases. With vague and nonspecific signs and symptoms, the initial diagnosis is usually delayed until the occurrence of extensive intra-abdominal spread through the contiguous peritoneal surfaces, ascites fluid, and rich lymphatics. Death usually occurs through progressive inanition and gastrointestinal tract obstruction that cannot be corrected through surgery due to extensive carcinomatosis [7].

Ovarian cancer should be regarded as not one but many diseases. Several histological subtypes have been described, with high-grade serous carcinoma as the most commonly diagnosed. However, its exact point of origin is still a matter of ongoing debate [12], and in-depth transcriptional analysis by The Cancer Genome Atlas project has defined four different transcriptional subtypes [13]. Still, the established standard strategy for treating advanced ovarian cancer has been maximum cytoreductive surgery and platinum based chemotherapy followed by surveillance for potential recurrence [14]. Complete debulking to no residual (0 mm vs 1–10 mm) was associated with improved overall survival and also impacted outcomes after the occurrence of relapsed disease, probably through the physical depleting of the reservoir of chemotherapy resistant clones. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is an option for treating patients with advanced bulky disease where upfront primary debulking surgery (PDS) is not technically feasible [15]. There is still doubt if the survival advantage of complete debulking is the same whether through PDS or IDS. Two randomized trials have shown similar survival rates for PDS and IDS, but recent evidence suggests that IDS correlates with a higher risk of developing platinum resistance [16]. This is most likely explained through the exposure of a high tumor volume with multiple tumor subclones to the stringent selection pressure of chemotherapy with subsequent expansion of resistant clones [17, 18]. The incorporation of antiangiogenic agents to standard therapy has brought only minor increments in PFS, while the addition of PARP inhibitors (PARPi) as maintenance therapy in BRCA mutated patients has significantly prolonged PFS with OS results still not mature [19, 20].

Despite high initial response rates, all too often relapse occurs, and subsequent treatment strategies maximize quality and length of life but are less likely to be curative. Rechallenge with platinum-based chemotherapy depends on the platinum free interval while surgery is limited to a subset of patients where OS results are still pending [21]. If not present from the first relapse, after several lines of treatment platinum resistant disease develops and represents a daunting clinical entity with limited therapeutic options and an overall survival of under 12 months [22]. Interestingly, about 15% of patients survive more than ten years however survivors of advanced stage disease represent a heterogeneous group that we have not yet determined or understood what makes them long-term survivors with more research needed for an understanding of this particular group [23].

Many of the clinical aspects previously presented depict evolutionary concepts such as spatial heterogeneity, temporal heterogeneity, and system induced selection pressure. Our current understanding of cancer has recently seen an exponential growth with the continuous technological development that offered the necessary tools to more precisely infer tumor cell dynamics. Hence, in the current review, we have systematically searched for articles that focused on the clonal evolution of ovarian cancer in an effort to offer the full landscape of research that has been done and highlight future research avenues given its characteristic features and connections to evolutionary biology. In the context that ‘Evolution has no eyes to the future’ [24] perfectly applies to the interaction between tumour and host microenvironment, we envision that using evolutionary principles we could be able to understand better the processes that drive tumor heterogeneity and select anticipative therapeutic strategies for improving patients’ outcomes.


The present systematic review was written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols statement. This review was also registered at PROSPERO under registration number CRD42018105413.

A comprehensive search of English written articles was performed on Web of Science – Science Citation Index Expanded, PubMed, EMBASE with no date restriction until July 2018. Secondary references were identified through screening of the reference lists of relevant studies. The following headings were used in the search strategy, including closely related words: genetic heterogeneity, clonal evolution, biological evolution, ovarian cancer. The detailed search strategy is presented in Table 1. After retrieving all articles generated by the search strategy and excluding duplicates, titles and abstracts were evaluated for eligibility. Included studies were restricted to human tissue, pathologically confirmed as epithelial ovarian cancer, and had a minimum of two paired samples per case. Subsequently, full text articles were retrieved and assessed for eligibility using the same search criteria, detailed in Tables 2 and 3

Table 1 Detailed search strategy
Table 2 PRISMA flowchart
Table 3 Summary of included articles in the systematic review


Early inferences of tumor heterogeneity

More than six decades ago, clinicians were asking to some extent, the same clinical questions as we do today but to a greater depth regarding ovarian cancer: “Do the cells of the metastasis or the recurrence behave as did the primary? Does the apparent acceleration in the downhill course of the patient depend upon an increase in the intrinsic malignancy of the tumor?”. The authors analyzed a number 550 samples from different areas of 36 patients and 12 temporally paired cases were evaluated by the authors in light microscopy, concluding that in most cases, the tumor structure remained unchanged [25].

Cytogenetic studies demonstrated that chromosomal abnormalities precede histologic changes. There was evidence for the same stem lines with identical chromosomal changes in bilateral cystadenocarcinomas, but without the possibility of drawing a conclusion towards a common ancestor hypothesis or a parallel malignant process in both ovaries, although the authors favored the latter given the similar pattern seen in bilateral cystadenomas [26]. Another cytogenetic study on 34 samples from 15 patients identified identical karyotypes in primary and metastatic samples from the same patient, without any evidence towards an increase in cytogenetic diversity during tumor progression [27]. Through the technique of inferred clonal cytogenetic evolution, a study conducted on three spatially separated samples of ovarian carcinoma from the same patient demonstrated the clonal evolution in ovarian cancer by mapping the frequency of occurrence of 18 different chromosomal breakpoints [28]. Performing repetitive karyotyping of malignant effusions during disease progression or after treatment administration in 9 patients evidenced aneuploidy, karyotyping diversity, and double minute chromosomes but in paired samples reported there were identical chromosomal alterations [29].

The use of restriction fragment length polymorphism probing in 7 patients demonstrated the coexistence of malignant cell clones, and the deletion of chromosome sequence 11p13-11p15.5 was considered a late event in disease progression [30]. Similar results were subsequently obtained in a larger series and with the addition of high-resolution comparative genomic hybridization (CGH), showing that metastases to the contralateral ovary had occurred as a late event in the clonal evolution [31].

A proof of principle study using PCR-based loss of heterozygosity (LOH) detection on flow sorted tumor cells demonstrated the feasibility of this method to confirm the monoclonal origin of different tumor cell populations and may be helpful in reconstructing the clonal evolution in solid tumors [32]. The evaluation of 10 microsatellites through PCR on 9 cases with primary tumors and paired metastases found an identical LOH spectrum in 4 cases, while in 5 cases the LOH patterns were different in the primary tumor and the metastatic nodes [33]. A study conducted on 8 cases with 21 samples showed that in 4 cases, the number of chromosomal aberrations in the metastatic site was lower than in the corresponding primary tumor site, in contradiction with the expected evolutionary finding [34]. Fishman et al. used comparative genomic hybridization to analyze the chromosomal profile of seven primary high grade serous ovarian cancer tumors and their paired metastases. A wide range of genetic alterations were present in the primary tumors however in 6 out of 7 metastatic lesions there were fewer genetic alterations or normal genomes, suggestive in the author’s opinion that this might reflect not ordinary metastases migrated from the primary tumor but developed independently as de novo carcinogenesis [35].

Molecular inferences of temporal heterogeneity

One of the first studies that analyzed in three cell line series the genetic changes associated with the transition from platinum sensitive to platinum resistant disease suggested they were not linearly related, and that platinum resistant disease emerges through the outgrowth of a pre-existing platinum resistant subclone under the selective pressure of treatment. Vast differences between sensitive and resistant clones were confirmed through multicolor fluorescence in situ hybridization and array CGH, with a higher genomic complexity at presentation than at relapse. A similar analysis of 6 paired tissue samples taken before and after three cycles of neoadjuvant chemotherapy revealed very few differences. The lack of differences after neoadjuvant chemotherapy could be attributed to a short exposure to treatment, survival of sensitive clones due to environmental reasons, or to the presence of a dominant clone at presentation [36]. Next generation sequencing of two of the above samples identified besides loss of homologous recombination (HR), that the tandem duplicator mutator phenotype is an ongoing mutator phenotype that arose early before lineage divergence. Its persistence may be responsible for the continuous evolution and might represent a novel, unknown deficit in DNA repair different from HR, with an estimated frequency of 12.8% [37]. Performing whole exome sequencing on ascites derived tumor cells at three time points found that besides TP53 mutations that were present at all time points, 89% of mutations found in recurrent tumors were also present at the beginning. This is concordant with previous reports that recurrent disease arises from the selective pressure of chemotherapy on pre-existent clones, even after two lines of chemotherapy [38]. A similar report underscored the situation in which the primary tumor is composed of mutationally heterogeneous clones, some of which give rise to the recurrences, with 41% shared somatic variants between 1 primary and 2 recurrent samples [39]. An extensive study that analyzed 31 paired primary and recurrent samples found extreme variability in heterogeneity within tumor pairs, likely caused by branched evolution in the primary tumor of a platinum resistant subclone that causes subsequent relapse. An average of 47 non-synonymous confirmed somatic mutations per tumor pair (range 5–147) were observed, with TP53 as the most frequently observed in 78% of cases, but few other genes were recurrently mutated. Out of the 1074 mutations, 58% were shared, whereas 15% (range 0–42%) and 27% (range 0–100%) were unique for the primary or recurrent samples. Similarly, 41% of the genome was affected in both primary and recurrent samples by copy number alterations. None of the clinical variables correlated with tumor heterogeneity. Interestingly, platinum sensitive tumors maintained HR deficiency when converting to a platinum resistant phenotype, suggesting that PARPi could be useful in this clinical situation, although they are currently approved only for platinum sensitive disease [40].

Molecular inferences of spatial heterogeneity

One of the first studies that conducted a comprehensive evaluation of intra-tumor heterogeneity included 110 samples from 16 patients with advanced high grade serous ovarian cancer. Screening for genetic alterations was done using microsatellite analysis and single nucleotide polymorphism (SNP) analysis, with maximum parsimony tree analysis used to infer the clonal relationships. Both approaches reached the same conclusions that there is extensive intratumor heterogeneity between all regions of the same patient despite their similar morphological appearance. By reconstructing their evolutionary history a monoclonal origin was suggested with no evidence of two or more ancestral lines. Common alterations included deletions on chromosomes 13 and 17, where BRCA1/2 and p53 genes are also located [41]. Employing similar methods, a subsequent study was conducted by the same group and focused on the relationship between primary and metastatic lesions. The authors found no cases in which the genetic profiles of all the metastases of a patient were the same, and there were no significant differences in the level of genetic heterogeneity between metastatic samples and primary tumors. The data presented support a model with a common clonal origin that becomes polyclonal from which clones with different genetic backgrounds have the potential to metastasize during the early and late stages of genetic divergence [42].

An in-depth approach that evaluated the genomic diversity at nucleotide, copy number, and gene expression scales in 31 samples from 6 patients revealed individualized extensive intratumor heterogeneity. A range of 31–137 unique mutations/case was present with 51.5% (range, 10.2–91.4%) mutations present in all samples of a case. Except case 1, all other harbored a p53 mutation present in all samples, making it the most stable genomic feature. In one case, the fallopian tube lesion was a metastatic implant, whereas in another case, it harbored two dominant clones that gave rise to two histologically distinct populations that had a common ancestor, indicating the early occurrence of polyclonal subpopulations, thus complicating even more the evolutionary origin of ovarian cancer in the fallopian tubes. Two paired temporal samples with almost identical genomic mutations characterized a case with extended survivorship. Analysis of plasma cell free circulating tumor DNA detected a range of 1–12 mutations from the ancestral clone, illustrating a rather narrow and heterogeneous phenomenon of tumor DNA shedding across cases [43]. A study that analyzed a higher number of 11 spatially separated samples from an advanced stage high grade serous ovarian cancer reported a lower rate of 6% for shared somatic mutations in all samples, and there was an early divergence of two primary clusters with one of them leading to the formation of a metastatic cluster with little accumulation of somatic mutations [44].

Serous tubal intraepithelial carcinomas (STIC) possess most of the genomic aberrations of other intraperitoneal metastases and only in 4 out of 8 cases they represent the evolutionary precursor lesions, while other STIC lesions might actually represent metastases of other anatomic sites with patients specific mutational signature characterizing high grade serous ovarian cancer (HG-SOC) as a heterogeneous disease without a specific mutational signature except patient specific ubiquitous TP53 mutations [45]. Phylogenetic analysis of bilateral ovarian cancer samples demonstrated a common ancestry, and early disemination, with marked intra- and inter-tumor heterogeneity, as previously presented [46]. Another study that reconstructed the evolutionary history from the RNA of 4 patients from 9 spatially separated samples for each case reached similar conclusions with early branching of peritoneal metastases, and the presence of multiple subclones at each tumor implant [47].

Tumor heterogeneity has been less frequently described in low grade SOC, however, on a study on 11 cases, 1 in 5 (20%) patients with RAS/RAF pathway mutations exhibited spatial and temporal heterogeneity, despite not receiving targeted treatment against the mutation [48].

An in depth study using the MEDICC phylogenetic algorithm demonstrated that high intra-tumour heterogeneity measured through a clonal expansion index was associated with longer survival, supporting the hypotheses that clonal expansion is a surrogate for genetic diversity that favors the development of treatment resistant clones. Evolutionary clades in the patient specific trees often agreed with the anatomical sites where the sample was taken, supporting the physical shedding from the invasive lesions in the fallopian tube. In 8 out of 9 evaluable cases, cells retained their metastatic potential, and a model of metastasis to metastasis spread was supported with significant branching of tree topologies. Investigating whether evolutionary change occurs at a constant rate, the study found that 2 out of 14 patients had significant non-clock-like evolutionary trajectories with potentially unknown mutator phenotypes. Neoadjuvant therapy induced only minor genomic changes compared to the overall changes, with an average of 46 new events. Phylogenetic reconstruction of relapsed samples in 2 cases demonstrated their early divergence from the common ancestor. In one case NF1 deletion, while present in the dominant population at relapse, was already present at diagnosis in a minor proportion with subsequent clonal expansion [49].

A study that performed clonal population profiling of spatially distinct intraperitoneal clones (68 tumor samples from 7 patients) through whole-genome and single-nucleus sequencing identified evolutionary features such as mutation loss, convergent evolution and time dependent mutational signatures. Interestingly, metastatic sites were composed of clonally pure or highly related clones with at least one tumor site in each patient containing multiple subclones. In 5 cases, intraperitoneal spread was monoclonal and unidirectional, while two cases exhibited polyclonal spread and reseeding underscoring two different migratory patterns [50]. The same group of authors recently showed that among the reasons for non-random distribution of malignant clones into the peritoneal cavity are the immune related cells of the tissue microenvironment that seem to have a role in shaping the evolutionary history of cancer cells. The authors defined three patterns of tumor infiltrating lymphocytes (TILs), reflecting their density and distribution within the tumor microenvironment, with ES-TIL being the most immunogenic population (substantial epithelial and stromal TILs) in comparison with S-TIL (stromal TILs) and N-TIL (sparse TILs). Within the same patients extensive spatial variation was observed, with 17 out of 31 patients harboring more than one pattern of TILs. Using four different measures for assessing sample clone complexity it was evident that samples with ES-TIL elicit immune editing of subclonal populations through T Cell tumor clone tracking with subsequent expansion of tumor cell populations that harbor neoantigen loss and/or human leukocyte antigen LOH. However, multi-site TIL diversity also implies that immune deficient sites might represent cradles of clonal diversity for subsequent disease relapse. Another important aspect is that specific classes of genomic aberrations such as fold-back inversions that are present in a significant proportion of cases lead to poor immunogenic responses whereas homologous recombination deficient tumors are associated with upregulated imune pathways. Overall, patient specific spatial diversity of the tumor microenvironment significantly influences the intraperitoneal dissemination, offering a new perspective on HG-SOC clonal evolution [51].

The utility of using cell free DNA to monitor treatment induced genomic changes was assesed on 20 patients with paired pre/post NACT tumor and plasma samples through targeted next generation sequencing (NGS) and found that it was minimal and larger studies are needed to determine the role of cell free DNA in the management of HGSOC [52]. Given that multiregion sampling is not always feasible, a study on 4 patients evaluated if the genomic information extracted from ascitic cells can accurately reflect the tumor burden. The ascitic cells genomes included 84–100% of the common mutations and a considerable fraction (22.9–75.8%) of shared mutations that were present in at least two distinct samples, thus offering a large view of the mutational lanscape of advanced ovarian cancer. Inferring the phylogenies of ascitic cells in relation with spatially separated tissue samples demonstrated an early evolutionary divergence and polyseeding [53].


Therapeutic strategies should be based on accurate knowledge of a tumor’s trajectory. It is obvious from the first published report that there were many questions regarding the heterogeneous clinical course of ovarian cancer however the lack of accurate tools to infer on its evolutionary history could not be surmounted even by a large number of evaluated samples, and no conclusions could be drawn except that in light microscopy in most cases there were no changes in tumor morphology [25].

In the following three decades, chromosomal banding techniques used in the study of spatially separated samples increased the analysis resolution. Similar complex chromosomal changes were observed in tumor samples, and there were no firm conclusions towards clonal heterogeneity [26]. It was suggested this was the result of a late metastatic process without any evolution after the emergence of the metastatic subclone, but the alternate hypotheses of an identical clonal evolution in both the primary and the metastatic lesions could not be excluded. Another proposed concept as a possible explanation for the identical chromosomal lesions seen in bilateral carcinomas was that of clonal dominance, the overgrowth of the primary tumor by cells that have a growth advantage [27]. In a proof of principle study, a diagram of the inferred cytogenetic changes of three spatially separated samples created a branching pattern for the clonal evolution of ovarian cancer [28]. This was in accordance with the general hypothetical model of clonal evolution presented by Nowel [54] and represented a new method that could be applied in the study of similar tumors from different patients or from sequential samples. Due to lack of genetic resolution, a study performing Giemsa banding chromosomal analysis of treatment or progression induced chromosomal changes reported the same clonal chromosomal aberrations [29].

Further studies that used more accurate techniques such as restriction fragment length polymorphism probing or high-resolution CGH identified the coexistence of malignant cell clones however the development of metastasis was considered a late event in evolution [30, 31]. After the introduction of PCR based LOH in ovarian cancer [32], a study based on a larger number of cases discovered a different spectrum of genetic alterations in metastases and confirmed the dissemination of only certain subclones [33], thus offering more precise interpretations of tumor evolution than previously studied based on chromosomal information [34, 35].

The advent of high throughput technologies demonstrated the existence of a common ancestor and revealed the scale of intratumor heterogeneity [41]. Analyzing the relationships between different metastatic samples of the same patient, there were no cases in which all metastatic samples of a patient were identical. It also became evident from the emerging data that it was in support of a model of clonal origin that soon after becomes polyclonal with different clones acquiring metastatic potential during early and late stages of genetic divergence [42,43,44,45, 47].

Extensive analysis of paired samples from diagnosis and recurrent disease showed that platinum resistant disease emerges from a minor pre-existent population through the selection pressure of chemotherapy with huge variability between the primary and recurrent disease [36, 38,39,40, 43, 46, 47], but a short administration of neoadjuvant chemotherapy didn`t seem to inflict significant genomic damage [36, 49]. Analysis of cell free DNA has been already tested in following the clonal dynamics of colorectal cancer patients [55]. Cells in the ascites fluid have been proven to reflect most the common somatic mutations of a patient as a potential future surrogate for monitoring the genomic burden of disease while circulating cell free tumor DNA has prooved non informative so far, owing to its small amount and presence of diluting nonneoplastic DNA [52, 53].

Subsequent analysis also showed that the presence of a tandem duplicator phenotype besides the well known homologous recombination deficiency as mechanisms that drive mutagenesis in a significant proportion of patients [37], suggesting that except TP53 other known actionable driver mutations are still elusive [38, 43, 44], contrary to the distinct entity of low grade serous ovarian cancer where cases with somatic mutations generally show stability across samples and time [48].

Previous observations that a stable genomic structure is associated with a longer overall survival [43] were confirmed through the phylogenetic quantification of heterogeneity that significantly predicted overall survival based on a clonal expansion index, in support of the hypotheses that high genetic diversity favors the development of treatment resistant disease [49].

Recent research has highlighted that most intraperitoneal mixtures are comprised in general of an oligoclonal population and at least one polyclonal site exists in every patient. Also, two non-random trajectories have been described, the first monoclonal and unidirectional and the second polyclonal with reseeding [50]. Theese patterns of spread seem to result from the spatial heterogeneity of the immune microenvironment that can actively shape the evolutionary history of cancer cells, with other clinical relevant interactions between mutator phenotypes and immune responses [51].

Cancer heterogeneity and cancer evolution represent a major challenge in front of effective therapy. A model of clonal evolution in ovarian cancer based upon some of the most important issues presented in this article is depicted in Fig. 1. Many of the published research on heterogeneity in ovarian cancer has been reffering to the genetic component, however heterogeneity in cancer is a more broader phenomenom that can potentially impact any of the aproximately ten hallmarks of cancer[56]. In ovarian cancer, heterogeneity beyond the genetic component can impact tumor cell subpopulations on cancer hallmarks such as sustained proliferative signaling, activation of the angiogenic switch, genomic instability, and evading immune destruction. In an effort to address this issues, several trials focused on specific tyrosine kinase inhibitors with some of them demonstrating activity against VEGFR [57]. Antiangiogenic drugs have been studied extensively as an addition to the chemotherapy backbone [58], but a clear benefit was seen only in a high risk patient population [59], however novel combinations are under way in order to augment their therapeutic potential in combination with immunotherapy [60] or PARPi [61]. In addition, the combination of PARPi with immunotherapy could be synergistic and is under evaluations in recent clinical trials [62]. Hence, future prospects should incorporate all aspects of cancer heterogeneity together with host and tumor microenvironment related factors.

Fig. 1
figure 1

Concept of clonal progression in cancer. Primary ancestral clone (P) has divergent evolution with early (M1) and late (M2, M4) acquisition of metastatic potential and re-seeding of metastases (M3). A high immune infiltrated microenvironment shapes clonal evolution. Pre-existent platinum resistant clones drive tumor relapse

Evolutionary computational methods in addition to the biomedical, genetic and clinical evidence we had so far can generate evidence based treatment strategies that can be further validated. A framework of tumor dynamics in ovarian cancer predicted the superiority of primary debulking surgery in a low volume disease setting [63], while other analyses focused on optimizing the sequence of chemotherapy in relation to immunotherapy [64] or targeting VEGF-mediated angiogenesis [65], approaches that can help us better understand the development of treatment resistance and design more efficient clinical trials. Characterization of growth and dissemination kinetics could also influence treatment strategies [66], while individual patient quantification of the clonal expansion index provides prognostic information that could further influence treatment intensity [49].

Methods such as high throughput single cell sequencing have recently offered the chance to study intratumor heterogeneity from the perspective of rare subclones [67], and together with novel evolutionary computational methods [68] they offer us the tools to have a real and acurate understanding of disease progression and optimal treatment strategies.

Availability of data and materials

The data analysed during the current study are available from the corresponding author on reasonable request.



Comparative genomic hybridization


High grade serous ovarian cancer


Homologous recombination


Interval debulking surgery


Loss of heterozygosity


Neoadjuvant chemotherapy


Next generation sequencing


PARP inhibitors


Primary debulking surgery


Single nucleotide polymorphism


Serous tubal intraepithelial carcinomas


Tumor infiltrating lymphocytes


  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.

    Article  CAS  PubMed  Google Scholar 

  2. Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31–7.

    Article  CAS  PubMed  Google Scholar 

  3. Dobzhansky T. Nothing in Biology Makes Sense except in the Light of Evolution. Am Biol Teach. 1973;35(3):125–9.

    Article  Google Scholar 

  4. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer. 2007;7(3):213–21.

    Article  CAS  PubMed  Google Scholar 

  5. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Eaton SB, Pike MC, Short RV, Lee NC, Trussell J, Hatcher RA, et al. Women’s reproductive cancers in evolutionary context. Q Rev Biol. 1994;69(3):353–67.

    Article  CAS  PubMed  Google Scholar 

  7. Longo DL, Young RC. The natural history and treatment of ovarian cancer. Annu Rev Med. 1981;32:475–90.

    Article  CAS  PubMed  Google Scholar 

  8. Rühli FJ, Böni T, Henneberg M. Hyperostosis frontalis interna: Archaeological evidence of possible microevolution of human sex steroids? HOMO- J Comp Hum Biol. 2004;55(1–2):91–9.

    Article  Google Scholar 

  9. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I Incidence Gynecol Oncol. 2015;138(3):741–9.

    Article  PubMed  Google Scholar 

  10. Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. PLoS ONE. 2015;10(6): e0127363.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Smith KR, Hanson HA, Mineau GP, Buys SS. Effects of BRCA1 and BRCA2 mutations on female fertility. Proc Biol Sci. 2012;279(1732):1389–95.

    CAS  PubMed  Google Scholar 

  12. Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17(1):65–74.

    Article  CAS  PubMed  Google Scholar 

  13. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

    Article  CAS  Google Scholar 

  14. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer. 2009;115(6):1234–44.

    Article  PubMed  CAS  Google Scholar 

  15. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  CAS  PubMed  Google Scholar 

  16. da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol. 2015;22(Suppl 3):S971–8.

    Article  PubMed  Google Scholar 

  17. van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013;49(15):3191–201.

    Article  PubMed  Google Scholar 

  18. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011;12(12):1169–74.

    Article  CAS  PubMed  Google Scholar 

  19. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer Nature Reviews Disease Primers. 2016;2:1–22.

    Google Scholar 

  20. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–505.

    Article  CAS  PubMed  Google Scholar 

  21. Bois AD, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501.

    Article  Google Scholar 

  22. Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133(3):624–31.

    Article  CAS  PubMed  Google Scholar 

  23. Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018;148(1):204–12.

    Article  PubMed  Google Scholar 

  24. Williams GC. Adaptation and natural selection; a critique of some current evolutionary thought. Princeton, N. J.: Princeton Univ. Press.; 1966. x, 307 p. p.

  25. Taylor HC Jr. Studies on the clinical and biological evolution of adenocarcinoma of the ovary. J Obstet Gynaecol Br Emp. 1959;66:827–42.

    Article  CAS  PubMed  Google Scholar 

  26. Knoerr-Gaertner H, Schuhmann R, Kraus H, Uebele-Kallhardt B. Comparative cytogenetic and histologic studies on early malignant transformation in mesothelial tumors of the ovary. Hum Genet. 1977;35(3):281–97.

    Article  CAS  PubMed  Google Scholar 

  27. Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S, Floderus UM, et al. BILATERAL OVARIAN-CARCINOMA - CYTOGENETIC EVIDENCE OF UNICENTRIC ORIGIN. Int J Cancer. 1991;47(3):358–61.

    Article  CAS  PubMed  Google Scholar 

  28. Roberts CG, Tattersall MH. Analysis of inferred cytogenetic clonal evolution in a metastatic human ovarian carcinoma. Cancer Genet Cytogenet. 1990;48(1):53–60.

    Article  CAS  PubMed  Google Scholar 

  29. Ioakim-Liossi A, Gagos S, Athanassiades P, Athanassiadou P, Gogas J, Davaris P, et al. Changes of chromosomes 1, 3, 6, and 11 in metastatic effusions arising from breast and ovarian cancer. Cancer Genet Cytogenet. 1999;110(1):34–40.

    Article  CAS  PubMed  Google Scholar 

  30. Vandamme B, Lissens W, Amfo K, De Sutter P, Bourgain C, Vamos E, et al. Deletion of chromosome 11p13–11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor. Cancer Res. 1992;52(23):6646–52.

    CAS  PubMed  Google Scholar 

  31. Micci F, Haugom L, Ahlquist T, Abeler VM, Trope CG, Lothe RA, et al. Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution. J Oncol. 2010;2010: 646340.

    Article  PubMed  Google Scholar 


    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zborovskaya I, Gasparian A, Karseladze A, Elcheva T, Trofimova E, Driouch K, et al. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: Intratumoral molecular heterogeneity. Int J Cancer. 1999;82(6):822–6.

    Article  CAS  PubMed  Google Scholar 

  34. Deger RB, Faruqi SA, Noumoff JS. Karyotypic analysis of 32 malignant epithelial ovarian tumors. Cancer Genet Cytogenet. 1997;96(2):166–73.

    Article  CAS  PubMed  Google Scholar 

  35. Fishman A, Shalom-Paz E, Fejgin M, Gaber E, Altaras M, Amiel A. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int J Gynecol Cancer. 2005;15(2):261–6.

    Article  CAS  PubMed  Google Scholar 

  36. Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010;29(35):4905–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, et al. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol. 2012;226(5):703–12.

    Article  CAS  PubMed  Google Scholar 

  38. Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol. 2013;229(4):515–24.

    Article  CAS  PubMed  Google Scholar 

  39. Mota A, Trivino JC, Rojo-Sebastian A, Martinez-Ramirez A, Chiva L, Gonzalez-Martin A, et al. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. BMC Cancer. 2015;15:11.

    Article  Google Scholar 

  40. Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, et al. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. Eur J Cancer. 2016;53:51–64.

    Article  CAS  PubMed  Google Scholar 

  41. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211(3):286–95.

    Article  CAS  PubMed  Google Scholar 

  42. Khalique L, Ayhan A, Whittaker JC, Singh N, Jocobs IJ, Gayther SA, et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers. Int J Cancer. 2009;124(7):1579–86.

    Article  CAS  PubMed  Google Scholar 

  43. Bashashati A, Ha G, Tone A, Ding JR, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 2013;231(1):21–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lee JY, Yoon JK, Kim B, Kim S, Kim MA, Lim H, et al. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer. 2015;15:9.

    Article  CAS  Google Scholar 

  45. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, et al. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016;6(12):1342–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Yin X, Jing Y, Cai MC, Ma PF, Zhang Y, Xu C, et al. Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer. Cancer Res. 2017;77(23):6551–61.

    Article  CAS  PubMed  Google Scholar 

  47. Chien J, Neums L, Powell A, Torres M, Kalli KR, Multinu F, et al. Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. Front Oncol. 2018;8:10.

    Article  Google Scholar 

  48. Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, et al. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014;14:982.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLoS Med. 2015;12(2):20.

    Article  CAS  Google Scholar 

  50. McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016;48(7):758–67.

    Article  CAS  PubMed  Google Scholar 

  51. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018;173(7):1755-69.e22.

    Article  CAS  PubMed  Google Scholar 

  52. Arend RC, Londono AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, et al. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Mol Cancer Res. 2018;16(5):813–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Choi YJ, Rhee JK, Hur SY, Kim MS, Lee SH, Chung YJ, et al. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. J Pathol. 2017;241(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  54. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8.

    Article  CAS  PubMed  Google Scholar 

  55. Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018;379(18):1754–65.

    Article  CAS  PubMed  Google Scholar 

  56. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013;8:277–302.

    Article  CAS  PubMed  Google Scholar 

  57. Katopodis P, Chudasama D, Wander G, Sales L, Kumar J, Pandhal M, et al. Kinase Inhibitors and Ovarian Cancer Cancers. 2019;11(9):1357.

    CAS  Google Scholar 

  58. Wang H, Xu T, Zheng L, Li G. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. Int J Gynecol Cancer. 2018;28(5):903–14.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Chelariu-Raicu A, Coleman RL, Sood AK. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit? Oncology (Williston Park). 2019;33(7).

  60. Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Alvarez Secord A, O’Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021;162(2):482–95.

    Article  CAS  PubMed  Google Scholar 

  62. Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, et al. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. Int J Mol Sci. 2022;23(7):3871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, et al. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 2021;118(25).

  64. Isaeva OG, Osipov VA. Different Strategies for Cancer Treatment: Mathematical Modelling. Comput Math Methods Med. 2009;10: 621782.

    Google Scholar 

  65. Finley SD, Chu L-H, Popel AS. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today. 2015;20(2):187–97.

    Article  CAS  PubMed  Google Scholar 

  66. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Navin NE. Delineating cancer evolution with single-cell sequencing. Sci Transl Med. 2015;7(296).

  68. Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F. Cancer Evolution: Mathematical Models and Computational Inference. Syst Biol. 2015;64(1):E1–25.

    Article  CAS  PubMed  Google Scholar 

Download references


Not applicable.


This study was supported by the Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca (Internal research grant number 3066/29/01.02.2018). Universitatea de Medicina si Farmacie "Iuliu Hatieganu",3066/29/01.02.2018,Paul Kubelac

Author information

Authors and Affiliations



PAC and PK designed the search strategy, analyzed and interpreted results. All authors had major contributions in writing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Patriciu Achimas-Cadariu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Achimas-Cadariu, P., Kubelac, P., Irimie, A. et al. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. J Ovarian Res 15, 67 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: